Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 521

Sort by

Sort Order Select

Journal Articles

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Geffen Kleinstern, PhD, Daniel R O'Brien, Brian Kabat, B.S., Kari G Rabe, Aaron D. Norman, Huihuang Yan, PhD, Celine M. Vachon, PhD, Shulan Tian, MS, PhD, Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Esteban Braggio, PhD, Susan L. Slager, PhD

Blood (2019) 134 (Supplement_1): 852.

https://doi.org/10.1182/blood-2019-124346

Published: 2019

Journal Articles

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, Bernard Sebastien, Hoai-Thu Thai, Raouf El-Cheikh, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Li Liu, Frank Campana, MD, Helgi van de Velde, MD PhD, Christine Veyrat-Follet, Dorothee Semiond, PhD PharmD

Blood (2019) 134 (Supplement_1): 1897.

https://doi.org/10.1182/blood-2019-128875

Published: 2019

Journal Articles

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Sheila K Pierson, MS, Laura Katz, MA, Christopher Sheild Nabel, MD PhD, Jason R Ruth, PhD, Sheila Diamond, MS, CGC, Hrishikesh Karvir, PhD, Fanyi Zhang, MS, Manjula P Reddy, MS, MSc, Mary Guilfoyle, MS, Craig Tendler, MD, Frits van Rhee, MD PhD, Philip Beineke, MS, Ana B Oromendia, PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2019) 134 (Supplement_1): 3599.

https://doi.org/10.1182/blood-2019-128284

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

William J Archibald, MDCPA, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Curtis A. Hanson, MD, Wei Ding, MD PhD, Amber Koehler, PA-C, MS, Eli Muchtar, MD, Suzanne R. Hayman, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Yucai Wang, MD PhD, Amie Fonder, PA-C, MS, Min Shi, MD PhD, Daniel L. Van Dyke, PhD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3037.

https://doi.org/10.1182/blood-2019-131154

Published: 2019

Journal Articles

Genomic Landscape of Sex Disparities in Multiple Myeloma

Susan Bal, MDMBBS, Kwangmin Choi, PhD, Omer Jamy, MD, Saulius K. Girnius, MD, Heather J Landau, MD, Luciano J. Costa, MD PhD

Blood (2019) 134 (Supplement_1): 3067.

https://doi.org/10.1182/blood-2019-127429

Published: 2019

Journal Articles

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

Daniel Hofbauer, Dimitrios Mougiakakos, MD, Maike Büttner-Herold, Frank Neumann, PhD, Jens Nolting, Savita Bisht, Robert Zeiser, MD, Shaima'A Hamarsheh, MSc,BSc, Stefano Ricagno, PhD, Mario Zaiss, Martin Eberhardt, Martin Boettcher, PhD, Katrin Bitterer, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 2314.

https://doi.org/10.1182/blood-2019-123958

Published: 2019

Journal Articles

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Luciano J. Costa, MD PhD, Simona Iacobelli, Marcelo C. Pasquini, MD, Riddhi Modi, PhD, Luisa Giaccone, Joan Bladé, MD PhD, Stefan Schonland, Andrea Evangelista, Jose A. Perez-Simon, MD PhD, Parameswaran Hari, MBBS, MD, Elizabeth E. Brown, PhD MPH, Sergio A Giralt, MD, Francesca Patriarca, Edward A. Stadtmauer, MD FACP, Laura Rosinol, MD PhD, Amrita Y. Krishnan, MD, Goesta Gahrton, MD PhD, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 259.

https://doi.org/10.1182/blood-2019-121367

Published: 2019

Journal Articles

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Charline Moulin, Romain Morizot, Thomas Remen, Hélène Augé, Florian Bouclet, Marion Divoux, Sandra Lomazzi, Caroline Dartigeas, MD, Anne Quinquenel, MD, Hélène Busby, MD, Cecile Tomowiak, Veronique Leblond, MD PhD, Catherine Thieblemont, MD PhD, Florence Cymbalista, MD PhD, Marie C Bene, PharmD,DPhil, Romain Guièze, MD PhD, Julien Broseus, MD PhD, Pierre Feugier, MD PhD

Blood (2019) 134 (Supplement_1): 4112.

https://doi.org/10.1182/blood-2019-128053

Published: 2019

Journal Articles

Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable

Stacey A Cranert, PhD, Maximilian Richter, PhD, Min Tong, MS, Leslie Weiss, MS, Yening Tan, MS, Eric M. Ostertag, MD PhD, Julia Coronella, PhD, Devon J Shedlock, PhD

Blood (2019) 134 (Supplement_1): 4445.

https://doi.org/10.1182/blood-2019-131839

Published: 2019

Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD

Blood (2019) 134 (Supplement_1): 5268.

https://doi.org/10.1182/blood-2019-123466

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alexander Chechetkin, Stanislav Bessmeltcev, Anastasiya Kuzyaeva, Alexander Sсhmidt, Alexey Kuvshinov, MD, Irina Pavlova

Blood (2019) 134 (Supplement_1): 5593.

https://doi.org/10.1182/blood-2019-130092

Published: 2019

Journal Articles

"Real-World" Peripheral T-Cell Lymphomas Experience in Portugal: Is There Reason for Optimism?

Ivan Dlouhy, Rita Gavancha, MD, Inês Coelho, MD, Catalina Gomez, MD, Inês Barbosa, MD, Susana Carvalho, MD, Maria Ceu Trindade, MD, Ana Filipa Moita, Gonçalo Esteves, MD, Paula Gameiro, Jose Cabecadas, Maria Silva, MD

Blood (2019) 134 (Supplement_1): 5287.

https://doi.org/10.1182/blood-2019-124485

Published: 2019

Journal Articles

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Matias Autio, Suvi-Katri Leivonen, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Teijo Pellinen, PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5230.

https://doi.org/10.1182/blood-2019-129681

Published: 2019

Journal Articles

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Clare Gould, Colm Keane, MD, Valentine Murigneux, M.Sc., Harald Oey, Jonathan Ellis, PhD, Simone Birch, MBBS, Jay Gunawardana, PhD, Dipti Talaulikar, Mark S. Hertzberg, MD PhD, Kimberley Jones, Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): 2778.

https://doi.org/10.1182/blood-2019-126537

Published: 2019

Journal Articles

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Blood (2019) 134 (Supplement_1): 1524.

https://doi.org/10.1182/blood-2019-129024

Published: 2019

Journal Articles

Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival

Blood (2019) 134 (Supplement_1): 1613.

https://doi.org/10.1182/blood-2019-123841

Published: 2019

Journal Articles

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Paolo Strati, MD, Koichi Takahashi, MD, Michael J. Keating, MD, Philip A. Thompson, MBBS, Christina Hinojosa, Diana Rodriguez, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, William G. Wierda, MD PhD, Andrew Futreal, PhD, Alessandra Ferrajoli, MD

Blood (2018) 132 (Supplement 1): 295.

https://doi.org/10.1182/blood-2018-99-111488

Published: 2018

Journal Articles

Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma

Rory McCulloch, FRCPath, MRCP, MBBS, Margie Berrow, Brian Wainman, Nicola Crosbie, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD

Blood (2018) 132 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2018-99-114528

Published: 2018

NARROW

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

Genomic Landscape of Sex Disparities in Multiple Myeloma

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

"Real-World" Peripheral T-Cell Lymphomas Experience in Portugal: Is There Reason for Optimism?

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only